CardioGenics Holdings Inc CGNH

CGNH Company Overview

CardioGenics Holdings Inc. (OTC: CGNH) is a Canada-based diagnostics and biotechnology company that historically focused on the development of point-of-care immunoassay technologies for cardiovascular and other disease testing applications. The company’s primary objective was the commercialization of proprietary diagnostic platforms designed to improve speed, sensitivity, and portability in blood testing environments. Its activities were primarily associated with the in-vitro diagnostics industry, particularly near-patient and rapid-testing solutions intended for hospitals, clinics, physician offices, and decentralized healthcare settings.

The company became known for its work on laser-based fluorescence immunoassay technologies and disposable biosensor cartridges intended to detect cardiac markers and other biomarkers. Public disclosures and OTC market records indicate that CardioGenics pursued strategic positioning around low-cost, rapid diagnostic testing with enhanced analytical sensitivity. However, publicly available operational disclosures became limited in later years, and current commercial scale, active revenue generation, and operating status are not consistently verified across recent public sources. Data inconclusive based on available public sources.